Vamsidhar Velcheti, MD, Oncology, New York, NY, NYU Langone Hospitals

VamsidharVelchetiMDFACP FCCP

Oncology New York, NY

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Oncology Program, New York University

Overview of Dr. Velcheti

Vamsidhar Velcheti, MD FACP FCCP is a medical oncologist with expertise in thoracic oncology and cancer immunotherapy. He is currently a Staff physician and Associate Director of Center for Immuno-Oncology Research at the Cleveland Clinic in Cleveland, OH. His current work focuses on novel immunotherapy strategies to treat lung cancer and biomarker discovery. He is interested in clinical trial design and incorporation of biomarker studies into early drug trials.

Education & Training

  • Yale University School of Medicine
    Yale University School of MedicineFellowship, Hematology/Oncology, 2010 - 2013
  • Ochsner Clinic Foundation
    Ochsner Clinic FoundationResidency, Internal Medicine, 2007 - 2010
  • Armed Forces Medical College Pune
    Armed Forces Medical College PuneClass of 2003

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2018 - 2022
  • OH State Medical License
    OH State Medical License 2013 - 2019
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Career development Award American Society of Clinical Oncology, 2015
  • Scott Hamilton CARES initiative research award 2015
  • ASCO Merit Award American Society of Clinical Oncology, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study
    Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia
    Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Non-small cell lung cancer (NSCLC) in octogenarians.
    Velcheti V., Viswanathan, A., Sainani, N., Grove, L., Suresh, R., Baggstrom, M.Q., and Govindan, R, Proc Am SocClinOnc, 2006; abst # 1855
  • Join now to see all

Lectures

  • Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCL... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
  • Cytokines in Cancer Immunotherapy: Recent Updates 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Overcoming Resistance to Immune Checkpoint Blockade 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

  • Renowned Lung Cancer Expert Joins Perlmutter Cancer Center
    Renowned Lung Cancer Expert Joins Perlmutter Cancer CenterSeptember 6th, 2018
  • Cleveland Clinic Cancer Center Experts Present Data at 2018 ASCO Annual Meeting
    Cleveland Clinic Cancer Center Experts Present Data at 2018 ASCO Annual MeetingJune 1st, 2018
  • Algorithm Identifies Lung Cancer Patients Who Should Have Chemotherapy
    Algorithm Identifies Lung Cancer Patients Who Should Have ChemotherapyMarch 12th, 2018
  • Join now to see all

Grant Support

  • Computerized Histologic Risk Predictor (CHiRP) for early stage Lung Cancers Objectives: To develop and validate a computerized histologic risk predictor (CHiRP) to identify which early stage NSCLC patients, following surgery, will receive additional benefit from adjuvant chemotherapyNational institute of health2018–2023
  • Cleveland Clinic Research Program Committee Research AwardCleveland Clinic Lerner Research Institute2014–Present
  • Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancerAmerican Society of Clinical Oncology2015–2018
  • Young Investigtator AwardAmerican Society of Clinical Oncology2012–2013

Committees

  • Member, Cancer Education Committee, American Society of Clinical Oncology 2015 - Present
  • Education Committee, American Society of Clinical Oncology 2015 - Present
  • Member, Protocol Review and Monitoring Committee, Case Comprehensive Cancer Center, Cleveland, Ohio 2014 - 2015
  • Member, Yale-New Haven Hospital-Graduate Medical Education Committee 2012 - 2013

Professional Memberships

Hospital Affiliations